Xenon Pharmaceuticals Inc. - Common Shares (XENE)
CUSIP: 98420N105
Q2 2017 13F Holders as of 30 Jun 2017
- Type / Class
- Equity / Common Shares
- Shares outstanding
- 92,799,600
- Total 13F shares
- 9,948,182
- Share change
- -128,251
- Total reported value
- $31,335,126
- Price per share
- $3.15
- Number of holders
- 39
- Value change
- -$1,135,510
- Number of buys
- 15
- Number of sells
- 11
Quarterly Holders Quick Answers
What is CUSIP 98420N105?
CUSIP 98420N105 identifies XENE - Xenon Pharmaceuticals Inc. - Common Shares in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 98420N105:
Top shareholders of XENE - Xenon Pharmaceuticals Inc. - Common Shares (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BVF INC/IL |
13F
|
Company |
3.2%
|
2,949,794
|
$11,799,000 | — | 31 Mar 2017 | |
| Capital World Investors |
13F
|
Company |
1.5%
|
1,429,000
|
$5,716,000 | — | 31 Mar 2017 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
0.78%
|
723,853
|
$2,895,000 | — | 31 Mar 2017 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.68%
|
634,812
|
$2,539,000 | — | 31 Mar 2017 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
0.47%
|
439,894
|
$1,760,000 | — | 31 Mar 2017 | |
| Invesco Private Capital, Inc. |
13F
|
Company |
0.41%
|
380,784
|
$1,523,000 | — | 31 Mar 2017 | |
| Opaleye Management Inc. |
13F
|
Company |
0.39%
|
360,000
|
$1,440,000 | — | 31 Mar 2017 | |
| Tekla Capital Management LLC |
13F
|
Company |
0.38%
|
350,000
|
$1,400,000 | — | 31 Mar 2017 | |
| Endurant Capital Management LP |
13F
|
Company |
0.37%
|
340,672
|
$1,363,000 | — | 31 Mar 2017 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.37%
|
339,614
|
$1,358,000 | — | 31 Mar 2017 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
0.35%
|
328,029
|
$1,312,000 | — | 31 Mar 2017 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.33%
|
310,179
|
$1,241,000 | — | 31 Mar 2017 | |
| SABBY MANAGEMENT, LLC |
13F
|
Company |
0.32%
|
296,478
|
$1,186,000 | — | 31 Mar 2017 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.23%
|
217,090
|
$868,000 | — | 31 Mar 2017 | |
| Artal Group S.A. |
13F
|
Company |
0.16%
|
150,000
|
$600,000 | — | 31 Mar 2017 | |
| Ghost Tree Capital, LLC |
13F
|
Company |
0.16%
|
150,000
|
$600,000 | — | 31 Mar 2017 | |
| Novo Holdings A/S |
13F
|
Company |
0.14%
|
127,563
|
$510,000 | — | 31 Mar 2017 | |
| K2 PRINCIPAL FUND, L.P. |
13F
|
Company |
0.13%
|
116,975
|
$468,000 | — | 31 Mar 2017 | |
| J. Goldman & Co LP |
13F
|
Company |
0.08%
|
72,400
|
$290,000 | — | 31 Mar 2017 | |
| State of New Jersey Common Pension Fund D |
13F
|
Company |
0.07%
|
65,000
|
$260,000 | — | 31 Mar 2017 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.06%
|
56,173
|
$225,000 | — | 31 Mar 2017 | |
| CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM |
13F
|
Company |
0.06%
|
55,000
|
$220,000 | — | 31 Mar 2017 | |
| Weiss Multi-Strategy Advisers LLC |
13F
|
Company |
0.03%
|
31,500
|
$126,000 | — | 31 Mar 2017 | |
| Virtu KCG Holdings LLC |
13F
|
Company |
0.03%
|
30,407
|
$122,000 | — | 31 Mar 2017 | |
| SCOTIA CAPITAL INC. |
13F
|
Company |
0.03%
|
26,203
|
$105,000 | — | 31 Mar 2017 | |
| NJ State Employees Deferred Compensation Plan |
13F
|
Company |
0.02%
|
20,000
|
$80,000 | — | 31 Mar 2017 | |
| Leith Wheeler Investment Counsel Ltd. |
13F
|
Company |
0.02%
|
16,075
|
$64,000 | — | 31 Mar 2017 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.01%
|
12,737
|
$50,000 | — | 31 Mar 2017 | |
| A.R.T. Advisors, LLC |
13F
|
Company |
0.01%
|
12,500
|
$50,000 | — | 31 Mar 2017 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.01%
|
10,386
|
$41,000 | — | 31 Mar 2017 | |
| INTERWEST VENTURE MANAGEMENT CO |
13F
|
Company |
0.01%
|
8,293
|
$33,000 | — | 31 Mar 2017 | |
| BANK OF MONTREAL /CAN/ |
13F
|
Company |
0.01%
|
7,137
|
$29,000 | — | 31 Mar 2017 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
3,616
|
$14,000 | — | 31 Mar 2017 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
2,464
|
$10,000 | — | 31 Mar 2017 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
1,055
|
$4,000 | — | 31 Mar 2017 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
700
|
$3,000 | — | 31 Mar 2017 | |
| Federation Des Caisses Desjardins du Quebec |
13F
|
Individual |
0%
|
50
|
$200 | — | 31 Mar 2017 |
Institutional Holders of Xenon Pharmaceuticals Inc. - Common Shares (XENE) as of Q2 2017
As of 30 Jun 2017,
Xenon Pharmaceuticals Inc. - Common Shares (XENE) was held by
39 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
9,948,182 shares.
The largest 10 holders included
BVF INC/IL, Capital World Investors, PERCEPTIVE ADVISORS LLC, ORBIMED ADVISORS LLC, Alyeska Investment Group, L.P., DAFNA Capital Management LLC, Invesco Private Capital, Inc., Tekla Capital Management LLC, SABBY MANAGEMENT, LLC, and Point72 Asset Management, L.P..
This page lists
39
institutional shareholders reporting positions in this security
for the Q2 2017 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2017 vs Q1 2017 Across Filers
Q1 2017 holders
37
Q2 2017 holders
39
Holder diff
2
| Investor | Q1 2017 Shares | Q2 2017 Shares | Share Diff | Share Chg % | Q1 2017 Value $ | Q2 2017 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.